Literature DB >> 22463747

miR-15a and 16-1 are downregulated in CD4+ T cells of multiple sclerosis relapsing patients.

Julio Cesar Cetrulo Lorenzi1, Doralina G Brum, Dalila L Zanette, Alessandra de Paula Alves Souza, Fernanda Gonçalves Barbuzano, Antonio Carlos Dos Santos, Amilton Antunes Barreira, Wilson Araujo da Silva.   

Abstract

The pathology of relapsing-remitting multiple sclerosis (RR-MS) is largely attributed to activated autoreactive effector T lymphocytes. The influence of microRNAs on the immune response has been shown to occur in different pathways of lymphocyte differentiation and function. Here, the expression of the miRNAs miR-15a/16-1 in PBMC, CD4(+), and CD8(+) from RR-MS patients has been investigated. BCL2, a known miR-15a/16-1 target, has also been analyzed. The results have shown that miR-15a/16-1 is downregulated in CD4(+) T cells, whereas BCL2 is highly expressed in RR-MS patients only. Our data suggest that miR-15a/16-1 can also modulate the BCL2 gene expression in CD4(+) T cells from RR-MS patients, thereby affecting apoptosis processes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22463747     DOI: 10.3109/00207454.2012.678444

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  16 in total

1.  miR26a modulates Th17/T reg balance in the EAE model of multiple sclerosis by targeting IL6.

Authors:  Rongwei Zhang; Ayong Tian; Jun Wang; Xueli Shen; Guoxian Qi; Yanqing Tang
Journal:  Neuromolecular Med       Date:  2014-11-02       Impact factor: 3.843

2.  Integration of MicroRNA databases to study MicroRNAs associated with multiple sclerosis.

Authors:  Charlotte Angerstein; Michael Hecker; Brigitte Katrin Paap; Dirk Koczan; Madhan Thamilarasan; Hans-Jürgen Thiesen; Uwe Klaus Zettl
Journal:  Mol Neurobiol       Date:  2012-05-02       Impact factor: 5.590

3.  3,3'-diindolylmethane ameliorates experimental autoimmune encephalomyelitis by promoting cell cycle arrest and apoptosis in activated T cells through microRNA signaling pathways.

Authors:  Michael Rouse; Roshni Rao; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  J Pharmacol Exp Ther       Date:  2014-06-04       Impact factor: 4.030

4.  Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease.

Authors:  Susan Achberger; Wayne Aldrich; Raymond Tubbs; John W Crabb; Arun D Singh; Pierre L Triozzi
Journal:  Mol Immunol       Date:  2013-12-25       Impact factor: 4.407

5.  Differential inflammatory microRNA and cytokine expression in pulmonary sarcoidosis.

Authors:  Agnieszka Jazwa; Lukasz Kasper; Maciej Bak; Mateusz Sobczak; Krzysztof Szade; Alicja Jozkowicz; Krzysztof Sladek; Jozef Dulak
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-11-01       Impact factor: 4.291

6.  MicroRNA dysregulation in multiple sclerosis.

Authors:  Omar de Faria; Craig S Moore; Timothy E Kennedy; Jack P Antel; Amit Bar-Or; Ajit S Dhaunchak
Journal:  Front Genet       Date:  2013-01-22       Impact factor: 4.599

7.  MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients.

Authors:  Michael Hecker; Madhan Thamilarasan; Dirk Koczan; Ina Schröder; Kristin Flechtner; Sherry Freiesleben; Georg Füllen; Hans-Jürgen Thiesen; Uwe Klaus Zettl
Journal:  Int J Mol Sci       Date:  2013-08-05       Impact factor: 5.923

Review 8.  Mechanism of T cell regulation by microRNAs.

Authors:  Juan Liu; Chang-Ping Wu; Bin-Feng Lu; Jing-Ting Jiang
Journal:  Cancer Biol Med       Date:  2013-09       Impact factor: 4.248

Review 9.  Expression, regulation and function of microRNAs in multiple sclerosis.

Authors:  Xinting Ma; Juhua Zhou; Yin Zhong; Linlin Jiang; Ping Mu; Yanmin Li; Narendra Singh; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Int J Med Sci       Date:  2014-06-02       Impact factor: 3.738

Review 10.  Is It worth Considering Circulating microRNAs in Multiple Sclerosis?

Authors:  Ferdinand Jagot; Nathalie Davoust
Journal:  Front Immunol       Date:  2016-04-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.